Alliancebernstein L.P. Grows Position in Humana Inc. (HUM)
Alliancebernstein L.P. increased its position in shares of Humana Inc. (NYSE:HUM) by 109.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 527,709 shares of the insurance provider’s stock after purchasing an additional 276,043 shares during the quarter. Alliancebernstein L.P. owned 0.37% of Humana worth $126,977,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its holdings in shares of Humana by 2,281.7% during the first quarter. BlackRock Inc. now owns 12,387,144 shares of the insurance provider’s stock worth $2,553,487,000 after purchasing an additional 11,867,056 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Humana by 3.6% during the first quarter. Vanguard Group Inc. now owns 9,734,767 shares of the insurance provider’s stock worth $2,006,725,000 after purchasing an additional 339,620 shares during the period. State Street Corp lifted its holdings in shares of Humana by 1.4% during the first quarter. State Street Corp now owns 6,274,811 shares of the insurance provider’s stock worth $1,293,487,000 after purchasing an additional 84,716 shares during the period. FMR LLC lifted its holdings in shares of Humana by 57.9% during the first quarter. FMR LLC now owns 5,050,853 shares of the insurance provider’s stock worth $1,041,184,000 after purchasing an additional 1,851,197 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of Humana by 84.3% during the first quarter. Renaissance Technologies LLC now owns 2,691,700 shares of the insurance provider’s stock worth $554,867,000 after purchasing an additional 1,231,400 shares during the period. 95.14% of the stock is owned by hedge funds and other institutional investors.
Shares of Humana Inc. (HUM) opened at 256.56 on Friday. The stock has a market capitalization of $37.08 billion, a PE ratio of 21.11 and a beta of 0.87. Humana Inc. has a 12 month low of $163.50 and a 12 month high of $259.47. The company’s 50 day moving average price is $247.64 and its 200 day moving average price is $229.85.
Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.08 by $0.41. The firm had revenue of $13.53 billion during the quarter, compared to analysts’ expectations of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same period in the previous year, the firm posted $2.30 earnings per share. Equities analysts anticipate that Humana Inc. will post $11.55 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Tuesday, August 29th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.60 annualized dividend and a yield of 0.62%. Humana’s dividend payout ratio is presently 13.06%.
COPYRIGHT VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/09/10/alliancebernstein-l-p-grows-position-in-humana-inc-hum.html.
A number of equities research analysts recently commented on the company. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $262.00 target price for the company in a report on Wednesday, June 7th. Leerink Swann lifted their target price on Humana from $250.00 to $265.00 and gave the stock an “outperform” rating in a report on Tuesday, May 30th. BidaskClub downgraded Humana from a “buy” rating to a “hold” rating in a report on Tuesday, June 13th. UBS AG reissued a “neutral” rating and issued a $237.00 price target (up from $205.00) on shares of Humana in a report on Wednesday, June 28th. Finally, Royal Bank Of Canada reissued a “hold” rating and issued a $214.00 price target on shares of Humana in a report on Monday, June 5th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the stock. Humana has a consensus rating of “Buy” and a consensus target price of $244.35.
In related news, SVP Brian P. Leclaire sold 4,971 shares of Humana stock in a transaction on Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the completion of the transaction, the senior vice president now directly owns 14,258 shares of the company’s stock, valued at $3,421,920. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Bruce D. Broussard sold 12,000 shares of Humana stock in a transaction on Friday, August 11th. The stock was sold at an average price of $251.88, for a total value of $3,022,560.00. Following the transaction, the chief executive officer now directly owns 80,086 shares of the company’s stock, valued at $20,172,061.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 60,566 shares of company stock valued at $15,326,746. 0.80% of the stock is currently owned by insiders.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.